Optimization of Oxazolidinones for Use in TB Drug Regimens

July 12, 2016 | Bethesda, MD, USA

Overview
Speakers
Barbara Laughon
NIH/NIAID, WGND
Richard Hafner
NIAID - Host-Directed Therapy
Ray Chen
Melvin Spigelman
TB Alliance, WGND
Philippe Prokocimer
Dan Johnson
George Drusano
Laura Via
Veronique Dartois
Kenneth Olivier
Meeting Recap

Goals for the Optimization of Oxazolidinone Workshop were to map the landscape of knowledge; plan for a larger meeting in the fall; and identifiy key individuals for participation in the larger meeting and of available data sets for presentation. The only clinical research on oxazolidinones are the NixTB study (linezolid), STREAM study, NExT trial (linezolid). The reason for urgency in discussing oxazolidinones is to fill the pipeline with more regimens involving these compounds. Discussions on which ones should progress and what kind of dosing should be used need to be made.

  • Agenda
    Welcome and Overview
    Barbara Laughon
    Current Research Questions
    Richard Hafner
    Experience with Linezolid in XDR TB
    Melvin Spigelman
    Tedizolid as a candidate for tuberculosis therapy
    Philippe Prokocimer
    Sutezolid as a candidate for tuberculosis therapy
    Dan Johnson
    Bridging pre-clinical and clinical development of novel TB regimens: An example employing Linezolid
    George Drusano
    In vitro and animal model comparative data
    Laura Via
    Research experience at Rutgers
    Veronique Dartois
    Experience with oxazolidinones for non-tuberculosis mycobacteria
    Kenneth Olivier
Downloads